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Abstract
The goal of this thesis was to evaluate the use of oblique needle trajectories in low dose 
rate prostate brachytherapy for large glands with pubic arch interference (PAI).
A planning study was conducted with five Subject prostate contours, from 3D Transrectal 
Ultrasound (TRUS) images, artificially enlarged to 60 cc to increase PAI. Oblique 
needles no template plans (OBL) and parallel needle no template plans (PNT), were 
compared to parallel needle template plans for each prostate. Iodine-125 (145 Gy 
prescription dose), 0.43 U air kerma strength, and needle angles < 15° were used. 
Beneficial improvements (p < 0.05) in dose parameters were shown for OBL plans (all 
organs), and PNT plans (only PTV VI00), when compared to template plans in paired 
one-sided t-tests.
An oblique plan was delivered to a 60 cc prostate phantom with PAI using a 3D TRUS 
guided mechatronic system. Seed placement accuracy was sub-millimeter in all 
directions.
Keywords
Prostate therapy; image guided surgery; medical robotics; ultrasound guidance; oblique 
needles; 3D TRUS; low dose rate; prostate brachytherapy
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List o f Abbreviations and Definitions
ADT -  Androgen Deprivation Therapy 
ANTPOST -  Anterior Posterior
CTV -  Clinical Target Volume. In LDR PB, it is equivalent to the Planning Target 
Volume (PTV). CTV is the volume that contains any tumour volumes or malignant 
tumour growth that can be located and identified through palpation, imaging, or clinical 
verification (i.e biopsies). It also includes malignant spread of the disease that may not be 
verified in the patient but is likely present. For example, the CTV includes microscopic 
extracapsular extension of prostate cancer. It has been shown through radical 
prostatectomy studies that all patients with prostate cancer between and including stages 
Tic and T2 have extracapsular extension of < 3 mm. Thus, for low dose rate prostate 
brachytherapy monotherapy, which may be offered for Tic and T2 cancers, the CTV 
includes the prostate and a 3 mm margin around the prostate.1
D90 -  A dose volume histogram (DVH) index that represents the minimum dose (% or 
units of J/kg = Gy) received by at most 90 % of the organ in question, (see Table 1.1 for 
explanations of other dose DVH indices)
DVH -  Dose Volume Histogram
ESTRO -  European Society of Therapeutic Radiology and Oncology
HDR -  High Dose Rate
FRE -  Fiducial Registration Error
LEFTRIGHT -  Left Right
LDR -  Low Dose Rate
OAR -  Organ(s) At Risk. These are critical structures, to which radiation dose must be 
limited.
X lll
OBL -  Oblique. It refers to brachytherapy plans that use oblique angle needles. In this 
thesis, these needles are not assumed to be constrained by a template.
PAI -  Pubic Arch Interference
PCa -  Prostate Cancer
PB -  Prostate Brachytherapy
PN -  Parallel template. It refers to brachytherapy plans that use needles parallel to the 
superior-inferior direction and constrained by the template grid.
PNT -  Parallel no template. It refers to brachytherapy plans that use needles parallel to 
the superior-inferior direction but which are not constrained by the template grid.
PTV -  Planning Target Volume. In LDR PB, it is equivalent to the Clinical Target 
Volume (CTV)
SAGITTAL CRYSTAL -  This is the side-firing linear transducer array of the 
ultrasound probe. It can be used to take a sagittal image, but more accurately, it takes 
images with a vertical axis orientation that is some linear combination of the 
LEFTRIGHT and ANTPOST directions. If the probe angle was neutral, the image is 
indeed sagittal.
SIDE-FIRING LINEAR TRANSDUCER ARRAY -  see sagittal crystal.
STE -  Seed Targeting Error 
SUPINF -  Superior Inferior 
TRUS -  Transrectal Ultrasound
VI00 -  A dose volume histogram (DVH) index that represents the volume (% or cc) of 
the organ in question receiving at least 100 % of the prescription dose, (see Table 1.1 for 





In Canada, 173,800 (51.7 % men, 48.3 % women) new cases of cancer and 76,200 (52.5 
% men, 47.5 % women) deaths due to cancer are expected to have occurred in 2010 . 
This excludes 75,000 new cases and 280 deaths due to non-melanoma skin cancer. 
Amongst all cancers (excluding non-melanoma skin cancer) affecting Canadian men, 
prostate cancer (PCa) is the most commonly occurring (27.4%) and third most common 
cause of death due to cancer (10.8%) .
1.1 Prostate Anatomy
The prostate’s main function is to produce prostatic fluid, a component of semen. The 
prostate is a walnut shaped exocrine gland organ that surrounds the prostatic urethra, and 





























Figure 1.1: The prostate relative to other structures, (a) Left-right (LEFTRIGHT) 
orientation of the prostate relative to other structures (Image from3), (b) Superior- 
Inferior (SUPINF) and Anterior-Posterior (ANTPOST) orientation of the prostate 
(Image from 4).
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The prostate is separated from the bladder and the penile bulb by the muscular 
bladder neck and urogenital membrane, respectively, which are involved in maintaining 
continence. The prostate is also anterior and adjacent to the rectum, and separated from it 
by only a thin layer of connective and fatty tissue.
The contemporary anatomical description of the prostate identifies the following 
regions or zones that have been uniquely identified based on their structure, location, 
histology and embryologie origin 5’ 6: 1) anterior fibromuscualar stroma, 2) periurethral 
glandular tissue, 3) transitional zone, 4) central zone, 5) and peripheral zone. These are 
represented in Figure 1.2.
Figure 1.2: Zonal anatomy as described by McNeal 6 (Image adapted from 7).
The peripheral zone is the most common site of PCa and makes up the posterior 
and apical region of the prostate6. The central zone, surrounds the periurethral tissue and
3
transitional zone. The periurethral tissue surrounds the proximal prostatic urethra, which 
is the portion of the urethra superior to the verumontanum (see Figure 1.2). The 
periurethral glandular tissue and transitional zone are the sole regions of enlargement in 
benign prostatic hyperplasia (BPH) 6. BPH is a condition in which the prostate enlarges 
due to tissue proliferation mostly within the transition zone, and it is more likely to affect 
older men6.
1.2 The Increased Need to Treat Low Stage Prostate Cancer
There has been a notable shift in the type of treatments offered, due to a shift in the 
demographic, stage of cancers detected, and a rise in cancer incidence in western 
countries 8'10. This has been attributed to the increase in prostate screening through 
prostate specific antigen (PSA) testing and biopsies11. PSA is a protease secreted by both 
normal and pathologic prostate cells. Its main role is to cleave polypeptide coagulants in 
semen. In PCa, total PSA tends to be increased and the ratio of free PSA to total PSA 
tends to be decreased. BPH also causes the total PSA to be increased.
As the screening has become more prevalent and is being performed on younger 
men, the incidence rates of prostate cancer have increased and the average age of men 
diagnosed with the disease has decreased. Also there has been a significant shift of 
incidences to lower stage localized cancers 9. This has increased the demand to treat 
younger patients with prostate cancer detected during the early stages of localized 
disease.9,11,12
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1.3 Prostate Brachytherapy as Treatment for Prostate 
Cancer
The type of treatments for PCa offered to patients can depend on stage, which describes 
the extent of the spread of cancer, and grade, which describes the aggressiveness of 
cancer. The most common treatment methods for PCa include one, or a combination of 
the following: radical prostatectomy, external beam radiation therapy (EBRT), prostate 
brachytherapy (PB), androgen deprivation therapy (ADT), and watchful waiting/active 
surveillance (WW/AS) n’12.
The word brachytherapy is partly derived from the Greek word brachys, meaning 
“short distance”. This is due to the fact that radioactive sources are placed within the 
tumour itself or nearby in the diseased organ. The procedure can be done by placing the 
sources in tissue either permanently or temporarily, and the two methods are respectively 
referred to as low dose rate (LDR) and high dose rate (HDR) brachytherapy to describe 
the dose rate of the source used.
LDR PB involves depositing 4.5 mm long, 0.8 mm diameter grain like seeds into 
the prostate. The number of seeds deposited ranged roughly between 50-120 depending 
on the size of the prostate, seed radioactivity (disintegrations per second), and average 
energy of the isotope used. In traditional temporary PB procedures, the LDR seeds are 
deposited by loading them in hollow needles, the tips of which are inserted up to the base 
of the prostate through the perineum. A depiction of this procedure is shown in Figure 
1.3.
The seeds contain radioactive material, usually Iodine-125 (1-125, half life = 60.2 
days, average energy = 28 KeV), or Palladium-103 (Pd-103, half life = 17 days, average 
energy = 21 KeV). Typical activities for 1-125 and Pd-103 range between l.lxlO7 -  
3.0xl07 Bq and 4.1xl07 -  6.3xl07 Bq, respectively (1 Bq = 1 disintegration per 
second).The amount and conformal shape of radiation dose can be controlled by the 
number and position of seeds deposited.
5
1-125 and Pd-103 decays by electron capture to excited states of Tellurium-125 
(Te-125) and Rhodium-103 (Rh-103), respectively. Te-125 and Rh-103 nuclei can relax 
by transferring its energy to an orbital electron through internal conversion (the dominant 
method) or through gamma emission. Following electron capture and internal conversion, 
characteristic x-ray fluorescence takes place.
Figure 1.3: LDR Prostate Brachytherapy setup, (a) (Images from 13,14) Shows the 
Patient is in the lithotomy position in a typical 2D Transrectal Ultrasound (TRUS) 
guided LDR PB setup, (b) Seeds, and needles with stylets, (c) (Images from15). A 
close up view of a template against a patient’s perineum, and a 2D TRUS probe 
cradled by a stepper unit, (d) (Image from 16). Seeds are typically around 4.5 mm 
long and 0.8 mm thick.
6
HDR PB usually involves inserting fewer hollow needles, which are not loaded 
with radioactive seeds. Rather, catheters are used to connect all needles to a device called 
a “remote after-loader”. The device inserts a flexible cable with a single “hot” radioactive 
source at its tip into each needle, one at a time. The amount of radiation dose given is 
controlled by the time spent, called the “dwell-time”, by the source at discretized 
locations along each needle. Dwell times can also be used to control the conformal shape 
of the dose. HDR dose is delivered in one or more dose fractions over the course of up to 
three days, and no sources or catheters are left within the patient after the procedure. In 
contrast to HDR, LDR PB takes approximately two hours of operating room time but the 
radioactive sources are permanently implanted within the patient tissue and left to slowly 
release most of the radiation dose within the first few months of radioactive decay.
HDR PB is used mostly in conjunction with external beam radiotherapy and is 
becoming a popular part of treatment courses for prostate cancers of intermediate to high 
risk factors 17. LDR PB is employed for early stage PCa with low risk factors 18. As HDR 
PB is not the subject of this thesis, it will not be discussed in greater detail.
In the era of PSA testing, Low Dose Rate (LDR) permanent seed prostate 
brachytherapy (PB) has emerged as a popular modality for localized prostate cancer. 
According to a survey of men registered to the Cancer of the Prostate Strategic Urologic 
Research Endeavor (CaPSURE), prostate brachytherapy now accounts for 13.3% of all 
surveyed prostate cancer treatments11. In that survey, the other treatments chosen by 
patients were prostatectomy, external-beam radiation, cryoablation, and androgen 
deprivation therapy. In Wallner et al.’s comparison of the approximate number of High 
Dose Rate (HDR) temporary prostate brachytherapy to that of LDR PB treatments, they 
estimate that in 2006, HDR PB constituted less than 10 % of all prostate brachytherapy 
procedures19.
In recent years, the development of mechatronics to improve needle insertion 
accuracy in brachytherapy procedures has emerged. This thesis examined the use of 
mechatronics and a novel 3D ultrasound imaging technique to guide needle insertions at 
oblique angles without the use of a fixed template grid. In the following sections of this
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chapter, we will describe volumes of interest during therapy (i.e. the prostate, urethra) 
and the recommended treatment doses to them, the limitations and contraindications of 
current LDR procedures such as pubic arch interference, our brachytherapy system 
design, and a review of mechatronic devices in the literature and previous planning 
studies. This will be followed by a statement of objectives, and an outline of the second 
chapter.
1.4 Dose calculation for low dose rate prostate 
brachytherapy
The dose calculation method for low dose rate prostate brachytherapy is outlined by the 
43rd task group organized by the American Association of Physicists in Medicine 
(AAPM)20. It provides a formula for the dose rate D(r,6) due to a single seed, at some 
distance, r, away from the center of a cylindrically symmetric seed, at an angle, 6, from 
the longitudinal axis of the seed (refer to the TG-43 formalism for a diagram). It 
approximates the dose rate to tissue by measuring the dose rate to water, which are 
similar for the energies used in low dose rate brachytherapy. The dose rate is defined as
D ( r , 6 ) = S k A
G(r, 0) 
G(r0, d0)
g(r)F(r,  9), 0 )
where r0 is the reference distance of 1 cm, and 0ois the reference angle o f -  A 
point at an angle 0o lies along the transverse bisector of the cylindrical seed.
Sk is the Air Kerma Strength of the seed and is provided by the manufacturer. It is 
defined as
Sjc = K(d)d2 , (2)
which is the air kerma rate K(d) for a specific source measured at some calibration 
distance d (usually 1 m) times the calibration distance squared. Air kerma is the kinetic 
energy released per unit mass, which is related to the air exposure by W/e, the average 
energy per ion (of one sign) needed to ionize air. Thus, the air kerma rate is a measurable
8
quantity that can be related to the air exposure rate measured by a dosimeter. Air kerma 










It is the dose rate to water (calculated in Monte Carlo simulations or measured in a water 
phantom) at a distance of 1 cm away from the middle of the source, along the transverse 
bisector of the source, per unit air kerma strength. The dose rate constant is a factor that 
relates the air kerma strength of a particular source to the dose rate that would be given to 
the medium (water) in the absence of a dosimeter.
G(r,9) is the geometry factor, which is simply the inverse square fall off for a 
point source (1/r ) or for a cylindrically symmetric source (see the TG-43 formalism for 
details). g(r)  is called the radial dose function, and accounts for attenuation and scatter in 
the medium, and seed self-filtration, along the transverse bisector of the source (e.g 
9 — 0O). Its value is obtained by measuring the dose rate at (r,0o), which is then 
multiplied with the reciprocal of the geometry factor at (r, 0O) (along the transverse 
bisector) to remove the effects of the inverse square fall of dose. Furthermore, it is 
normalized by the radial dose function measured at the reference point (r0,0O).
Fix, 0) is called the anisotropy function. It accounts for the anisotropy or angular 
dependence of dose due to attenuation, scatter in the medium, and seed self-filtration, 
caused by photons travelling obliquely through the cylindrically constructed seed. It is 
obtained by measuring the dose rate at (r, 9) (various distances and angles), then 
multiplying it by the reciprocal of the geometry factor at (r, 9) to remove the effects of 
the inverse square fall off of dose. Furthermore, it is normalized by the anisotropy 
function measured at (r, 0O) (along the transverse bisector).
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The radial dose function and anisotropy function have the inverse square fall off 
effects removed to more the accurately interpolate between the measured points, 
particularly for points close to the source where there are high dose gradients. Upon 
expanding the entire right side of equation (1) (see TG-43 20 for exact definitions of g(r)  
and F(r, 6)), one notices that the appropriate factors all cancel to leave only the dose 
rate. Thus with the dose rate constant, air kerma strength, and a set of look up tables for 
the radial dose function and anisotropy function for a particular source, one can calculate 
the dose rate to water at any point (r, 9) (of course interpolation is required between 
measured points). The dose rate can then be multiplied by the mean life of the isotope to 
acquire the total dose at an arbitrary point (r, 9).
1.5 Target and Organs At Risk volume definitions and plan 
quality metrics in LDR PB
1.5.1 Imaging anatomy with 2D Transrectal Ultrasound (TRUS)
Figure 1.4: Sagittal and transverse views of the prostate that can be taken with a 2D 
TRUS probe, (a) Sagittal view taken with the side firing linear array, (b) Transverse 
view that can be taken with the side firing convex array.
The most common imaging guidance method for PB procedures is by 2D Transrectal 
Ultrasound (TRUS) l7,18. It has gained popularity for use with PB (and other transperineal 
procedures) for its low cost, high temporal resolution, small operating room foot print, 
ability to resolve the prostate anatomy as well as local extent of PCa in some cases, and 
the fact it is non-ionizing as opposed to CT for example ’ . Typically, a TRUS
probe for brachytherapy consists of a side firing linear array transducer for sagittal 
imaging and a side firing convex array for transverse imaging. Using 2D TRUS, one can 
visualize the prostate, the pubic arch, the prostate/bladder interface (best done using the
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sagittal array), and the urethra if a catheter or aerated gel is inserted. Figure 1.4 above 
shows sagittal and transverse views of the prostate taken with a 2D TRUS probe.
1.5.2 Volume definitions
The European Society of Therapeutic Radiology and Oncology (ESTRO) has 
summarized the numerous recommendations in literature concerning volume definitions 
and the dose requirements for LDR PB ’ . LDR PB is effective as a sole treatment 
method for prostate cancers between the stages TIC to T2B, inclusively 18. In such cases, 
cancer spread beyond the prostatic capsule, referred to as extra-capsular-extension (ECE), 
is common but confined to within 3 mm outside the prostatic capsule 181. For this reason, 
if LDR PB is the sole treatment method employed, a 3 mm maximum margin around the 
prostate is added, as shown in Figure 1.5.
The volume of the prostate plus the 3 mm thick shell created by the margin 
constitutes the Clinical Target Volume (CTV), which is the theoretical minimum volume 
containing all tumour lesions for TIC to T2B cancers. The Planning Target Volume 
(PTV) is traditionally defined in radiotherapy as the CTV plus a margin to account for 
organ motion or delivery and setup inaccuracies. In LDR PB, this additional margin is 
negligible such that the CTV and PTV are equivalent, and they can simply be referred to 
as the Target. This is because the prostate is relatively immobile during brachytherapy 
needle implantation due to being anchored with needles and additional set up and motion 
errors can be made negligible with good technique.
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Figure 1.5: Non uniform Prostate margins, (a) Sagittal view of the PTV with respect 
to the other organs, (b) Transverse view of the PTV. The margin is negligible at the 
base (between the bladder and prostate) and rectum to prevent inserting needles 
into the bladder and overdosing the rectum, respectively.
Organs at risk (OAR) are the organs that may potentially receive a certain level of 
dose that may lead to organ failure or complications for the patient. These organs are 
usually the more dose sensitive organs in the imediate vicinity of the target. Although 
theoretically, any non-prostatic tissue should be spared from excess dose, dose 
constraints are so far only defined explicitly for the urethra and rectum. Other OARs are 
the penile bulb, bladder, and nerve bundles near the prostate. Due to the rectum being 
dose sensitive, the margin to create the PTV is made to be negligible at the prostate’s 
posterior edge to prevent overdosing the rectum. Though the bladder muscles are not as 
radiosensitive as the rectum or urethra, the margin is also made negligible at the 
prostate’s base to prevent accidental seed insertions into the bladder wall. Figure 1.6 
below shows sample segmentations of the OARs and Target (PTV) in a 3D TRUS image.
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Figure 1.6: Slices of a 3D Transrectal Ultrasound (TRUS) image with segmentations
of the prostate (purple), urethra (gold), rectum (pink), pubic arch (orange). The 
narrowest pubic arch opening has been projected throughout the image in the 
superior-inferior direction, (a) Sagittal view; (b) Transverse view, also showing the 
narrowest pubic arch opening.
1.5.3 Recommended Plan Quality Metrics
The dose distribution from an LDR plan is determined by the seed positions, orientations, 
energy, and activity. Dose distributions that are generated prior to, during, and after the 
operation are called pre, intra-operative, and post plans. Using the 3D dose distribution 
and segmented organs, one can generate dose volume histograms (DVH) for each organ. 
The quality of plans can be judged using the dose volume histogram parameters 
recommended by the European Society of Therapeutic Radiation Oncology (ESTRO) 1. 
An example of a DVH curve is shown below in Figure 1.7.
DVH curves show what volume (or percent volume) of an organ (y-axis) receives 
at least a certain amount of dose (x-axis). For example, for a given dose value D (on the 
x-axis of Figure 1.7), the corresponding volume value can be computed by counting the 
number of voxels (for a particular organ) that receives a dose of D or more. ESTRO 
recommends lower and upper limits of dose intended for the various organs during the
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pre, intra, and post-operative stages. For example, in a pre-plan, it is recommended that at 
least 95% of the voxels within the planning target volume (PTV) must receive a 
minimum of 145 Gy, which is the prescription (Rx) dose for LDR PB using 1-125 seeds. 
The metric that expresses this volume is the PTV VI00, which is the volume of PTV 
receiving at least 100% or more of the prescription.
In the following work presented henceforth, an additional custom metric to 
evaluate the quality of plans was used. It was calculated as the PTV VI00/# seeds. It is a 
measure of how much dosimetric coverage is achieved per seed, which gauges how 
efficiently the seeds are distributed. Table 1.1 shows a summary of the plan quality 
metrics used.
Dose Volume Histogram (DVH) curve
Figure 1.7: An example DVH curve for the Target (solid), Urethra (dashed) and 
Rectum (dotted). The vertical components of the intersection points between the 
DVH curves (blue) and the solid black lines represent the organs’ volume DVH 
indices such as VI00. The horizontal components of the intersection points between 
the Rectum dvh curve and the dotted horizontal black lines represent the rectum 
dose DVH indices, D2cc, and DO.lcc. These volume and dose DVH indices and there 
criteria are described in Table 1.1.
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Table 1.1: ESTRO dose volume histogram (DVH) index recommendations for LDR 
PB pre-plans plus the custom efficiency metric PTV V100/# seeds. Rx = 145 Gy, the 
prescription dose.
Organ DVH index (units) Criteria
PTV VI00 (% volume) -  volume of the organ 
receiving at least 100 % of Rx.
> 95 %
VI50 (% volume) -  volume of the organ 
receiving at least 150 % of Rx (217.5 Gy)
< 50 %
V200 (% volume) -  volume of the PTV 
receiving at least 200 % of Rx (290 Gy)
None explicitly specified
D90 (Gy) -  minimum dose to 90% of the 
volume
> 100 % Rx
PTV VI00/# seeds none
Urethra VI00 (% volume) 100 %Rx
VI20 (% volume) -  volume of the organ 
receiving at least 120 % of Rx (174 Gy)
0 % Rx
D30 (Gy) -  minimum dose received by at 
most 30 % of the organ volume
< 130 % = 188.5 Gy
D10 (Gy) -  minimum dose received by at 
most 10 % of the organ volume
< 150% = 217.5 Gy
Rectum R100 (cc) -  like VI00 but for the rectum, 
and expressed in cc.
< 1 cc
D2cc (Gy) -  minimum dose received by at 
most 2cc of the Rectum
< Rx
DO.lcc (Gy) -  minimum dose received by 
at most 0.1 cc of the Rectum
< 200 Gy
* VI20 = 0% Reflects the upper dose limit for the urethra used at the London Regional 
Cancer Program. ESTRO recommends an upper limit of V I50 = 0 % for the urethra.
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1.6 Limitations to current LDR PB techniques
1.6.1 2D Ultrasound Guidance with a 0.5 cm Stepper
Figure 1.8: Discretized template grid.(a) shows the designation of the base and apex 
being the superior (cranial) and inferior (caudal) edge of the prostate; b) shows the 
result of 0.5 cm interval images reconstructed as a volume. Using these images to 
segment anatomy is both time consuming and inaccurate; (c) -  (e) examples of axial 
images taken at various stepper positions.
Although there have been many recent advances in LDR PB, the conventional 
methodology has many limitations. Imaging is performed in 2D using a transrectal 
ultrasound (TRUS) probe. In the typical 2D method, the volume is constructed from a 
series of axial images acquired while positioning the probe at discretized positions in the 
superior-inferior (SUPINF) direction. The stepper (see Figure 1.8c), which positions the 
probe in the SUPINF direction can only move the ultrasound probe in 0.5 cm increments.
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Using such volumes, shown in Figure 1,8b, identification of the anatomy, needles, and 
seeds can be difficult and time consuming. Moving the probe in this direction also carries 
the risk of allowing the prostate to roll off the probe and move or rotate in the anterior- 
posterior direction or plane, thus increasing the potential for prostate motion.
1.6.2 Discretized Template Grid
The brachytherapy template limits needle positions to a 0.5 cm spaced grid and 
their orientation to be all parallel in the superior/inferior (SUPINF) direction (such 
trajectories will henceforth be referred to as parallel). The discretized grid spacing makes 
it difficult to plan and insert needles in non-template positions that may be more 
dosimetrically optimal. While the template requires all needles to be parallel, non-parallel 
needle trajectories (henceforth referred to as oblique) may be more dosimetrically 
optimal than parallel ones, depending on the anatomy of the patient.
1.6.3 Pubic Arch Interference in Larger Prostates
Oblique needle trajectories that cannot be delivered with a template in place may be 
beneficial for patients with pubic arch interference (PAI) 22-25. PAI is the obstruction of 
transperineal needle insertions due to the pubic arch being too narrow or its position 
being too posterior compared to the targeted organ. In PB, PAI occurs when the antero­
lateral parts of the prostate is covered by a narrow pubic arch. An example of this is 
shown in Figure 1.9b, which shows the overlap between the prostate and pubic arch 
outlines that have been projected to a 2D axial plane. The figure thus shows that PAI 
would prevent any parallel needles (trajectories that are perpendicular to the axial plane) 
from being delivered to the overlapped regions of the prostate. Therefore, a natural 
consequence of PAI to PB is that there could be unacceptable under dosing of the antero­





Figure 1.9: Pubic arch interference(a) Image from26, the position of the pubic arch 
in relation to the pelvis, (b) Image from27. Pubic arch interference in a CT slice, 
showing overlapping regions between the prostate outline and the pubic arch.
PAI is more likely to occur in patients with a narrow pubic arch and a large 
prostate, which is the reason why many brachytherapy centers do not offer LDR PB as a 
treatment option to patients with prostates larger than 50 cc. The upper limit for prostate 
volumes vary depending on the institution but recommendations in literature point to 
upper limits of approximately 50 cc or 60 cc. The American Brachytherapy Society 
(ABS), for example, warns brachytherapists of the increased risk of complications in 
attempting to treat patients with prostate volumes > 60 cc 28.
The amount of PAI, however, is not solely dependent on either the pubic arch size 
or the prostate volume but rather the combination of the two 24,25. In fact, both are highly 
variable from one patient to the next. Although the question of what amount of PAI is 
permissible has not been standardized, investigators at the University of Washington and 
the Seattle Prostate Institute have made a reasonable recommendation based on their 
pubic arch studies. They have proposed that PAI is measured as a distance along a 
trajectory perpendicular to the pubic arch, and as the amount of overlap between the 
largest section of prostate and narrowest section of pubic arch. They have been the first to 
recommend a formal upper PAI limit of 1 cm or obstruction of 25 % of the prostate
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diameter 23,24.
In the past, the following methods of PAI avoidance have been employed ^ ’ ’
: 1) having a patient undergo androgen deprivation therapy (ADT) to reduce the prostate 
size prior to surgery; 2) extending the lithotomy position to shift the pubic arch 
anteriorly; 3) angling the tip of the probe anteriorly and the rear posteriorly; 4) bending 
the needle to deflect it and thus avoid PAI; and 5) removing the template and inserting 
the needle free hand to achieve severe needle angulation. The third method causes the 
template itself to be angled such that needles may be inserted through the template to 
avoid minor pubic arch interference. The latter three methods are motivated by the 
potential for oblique needle placements to avoid PAI and achieve anterior-lateral dose 
coverage of the prostate to meet dosimetric requirements.
The above methods have major drawbacks. ADT may have consequences to 
quality of life and sexual function for some patients, and can be costly 31’32. The other 
methods of PAI involve inaccurate intra-operative a d  h o c  adjustments that can introduce 
uncertainties in patient setup, prostate localization, and needle and seed deliveries during 
the procedure.
Although PAI can potentially be solved for some patients by using oblique needle 
trajectories during the planning and delivery stages 22-24>25’33-35,29^ -t  m u s t  
accurately and precisely. Failing to do so can damage the urethra, rectum, and penile bulb 
and lead to complications and major consequences to the patient’s quality of life. Using 
oblique needles thus requires a precise mechanical device for accurate positioning as well 
as a treatment planning and delivery system that is capable of planning and delivering or 
guiding them into the prostate. A compact, 4 degree of freedom (DoF) needle positioning 
mechatronic apparatus and 3D TRUS guided planning and delivery system has therefore 
been developed in our laboratory for this very task 36.
In the past, few institutions have performed dosimetric planning studies to test the 
feasibility of delivering oblique needles 33‘35. Quite a number of institutions have 
developed mechatronically assisted brachytherapy systems 36‘4\  A description of our 
mechatronic device, followed by a review of mechatronic devices developed for LDR PB
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as well as previous dosimetric planning studies 33-35 to test the benefits of oblique needles 
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Figure 1.10: The mechatronic device.The device’s front arm and back arms are 
counterbalanced and can be fixed in position using friction brakes. The needle can 
be guided with the aid of real time visual feedback of the needle’s intended and 
actual trajectory. This can be done using the transverse transducer (as shown 
above) or using the sagittal transducer. The 3D image (labeled above as the 3D cube 
view) can be used to view any arbitrary plane in the image, or be used to visualize 
the intended and actual needle trajectories.
Recently, a new compact 4 degree of freedom (DoF) needle positioning mechatronic 
apparatus and 3D TRUS guided planning and delivery system has been developed in our 
laboratory for accurately depositing seeds and overcoming PAI j6. The delivery of a 
needle into a phantom using the system is shown in Figure 1.10.
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The system is capable of allowing a brachytherapy team to perform all aspects of 
a brachytherapy treatment process. This includes 3D TRUS image acquisition, 
segmentation on 3D TRUS, HDR and LDR PB pre-planning and live planning, delivery, 
and post planning. Planning can be generated manually with or without templates. 
Without the use of a template, needles can be manually placed in arbitrary positions and 
angled to compound angles (less than 30 degrees) to have both a pitch and yaw.
1.7.1 Mechatronic device
The backbone of the mechatronic device shown in Figure 1.10 consists of a cylindrical 
shaft, on which the components of the device are mounted. The needle guidance linkage 
and encoders are mounted onto the shaft. The TRUS probe is mounted above and parallel 
to the central shaft and is directly coupled to a probe mover (see probe mover in Figure 
1.10), which is mounted on the inferior end of the shaft. The mover is a motor that rotates 
the probe about its long axis. A mechanism to change the probe’s SUPINF position using 
a dial (see Manual stepper knob in Figure 1.10) is also mounted onto the shaft. The 
physician can use the dial to, for example, center the sagittal transducer below the 
prostate or move the axial transducer to a desired SUPINF position. The front and back 
arms, shown in Figure 1.10, each control two degrees of freedom. Each arm consists of a 
parallelogram linkage, which is pinned to the shaft. The parallelogram can collapse as 
well as rotate about its pinned vertex, thus having two degrees of freedom. The needle 
guide is connected to the front parallelogram linkage by means of a spherical coupling. 
The rear parallelogram linkage connects to the same kind of spherical coupling, which in 
turn connects to the needle guide via a telescoping shaft.
The spherical coupling provides a remote center of motion (RCM) for the front 
and back arms. The RCM of the front arm is intersected by the needle path, and the RCM 
of the rear is aligned to the axis of the telescoping needle guide. The RCM of the front 
arm is always coincident with the axial plane of the device’s superior most face, which is 
meant to be in contact with the patient’s skin. The anterior-posterior (ANTPOST) and 
left-right (LEFTRIGHT) position of the front RCM is controlled by moving the front
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arm. Moving the rear arm then causes the needle path to pivot about the RCM of the front 
arm. The actual position of the needle trajectory, as determined using encoders, is 
visually guided to match the intended needle trajectory on the arm tracking interface of 
the image guidance/treatment software. Once in the desired position, the arms can be 
locked, and the needle insertion can be carried out with the aid of the needle guidance 
software interface.
Phantom experiments have been previously conducted at our laboratory by Bax e t  
a l ,36 to test the accuracy of various parallel and oblique needle insertions using our 
system. In that study, Bax e t  a l. employed a motorized version of the device to control 4 
DoF’s for needle positioning and angling. With the motors deactivated, the device is 
completely back driveable and allows the physician to manually control the needle 
trajectory with the aid of image guidance.
Since the publishing of experimental results based on the motorized version of the 
mechatronic device, we have chosen to remove the motor assemblies driving the 4 DoF’s 
and have made the device significantly more compact and lightweight at only 3 kg 
(without the probe). The result is the device shown in Figure 1.10. Additionally, the non- 
motorized version is much easier to introduce into the clinic from a safety stand point, 
while capable of being as accurate as its motorized counterpart. Motorized clinical 
devices have inherent safety concerns associated with them. For example, an electrical 
surge can disable a system, which may in turn cause motors to immediately return to their 
home positions. In the case that a needle inserted into a patient is still bound to the 
robotic device, this can have disastrous consequences for the patient.
1.7.2 3D Imaging
3D TRUS image is acquired by rotating a probe about its long axis and acquiring a series 
of 2D sagittal images, which are reconstructed into a 3D volume 21,46. The rotational 
angle of the probe is motor controlled. An encoder tracks the superior/inferior (SUPINF) 
position, which can be manually adjusted using a dial.
This technique of 3D TRUS imaging offers a number of benefits compared to the
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traditional method of constructing images from 0.5 cm spaced axial images. 3D volumes 
are acquired very quickly (~3 sec). The use of the 2D sagittal images to reconstruct the 
3D volumes negligibly degrades the resolution of sagittal images in the SUPINF direction 
(3 ± 3 %) 46 . The 3D anatomical information is thus preserved, which can be used to 
better segment organs of interest more accurately . The system makes use of 3D semi­
automatic prostate segmentation tools, for example, which helps segment the prostate 
more quickly and accurately than the traditional method of segmenting structures 
manually on axial images 47. At the present time, the technologies developed at our 
laboratory to acquire 3D TRUS images and perform segmentations have been licensed 
for use in commercial products such as Nucletron’s FIRST system .
An important application of 3D TRUS to PB is that it can facilitate the imaging of 
oblique needles that have trajectories non-coincident with a US beam from either the 
sagittal or axial transducer. Such oblique needle trajectories may be beneficial for 
avoiding PAI or delivering seeds to specific areas of the prostate lacking in adequate 
dose.
1.8 Review o f Mechatronically Assisted Systems for LDR 
PB
Various institutions have developed ultrasound guided mechatronic systems for accurate 
transperineal needle insertions using ultrasound or magnetic resonance image guidance. 
Only ultrasound guided systems will be discussed henceforth since ultrasound is the 
imaging modality of choice used by most LDR PB institutions (the benefits of ultrasound 
guidance has been explained previously in section 1.5.1).
Nucletron’s FIRST system 37 employs a probe mover and 3D TRUS imaging and 
visualization system that were developed at our laboratory. Their system uses the 
traditional template approach, but utilizes an inverse planning algorithm based on fast 
simulated annealing (IPSA) developed by Pouliot et al.48. According to an institution that 
has reported on their experience with this system, pre-plans are designed but the planning 
is then redone intra-operatively 49. Needles are inserted according to this intra-operative
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plan and their positions are updated according to the actual location of the inserted 
needles. This is possible with the aid of live plan updating and probe rotating 
functionalities developed in our laboratory. A plan is then re-created according to the 
updated needle positions, and seed depositions and needle retractions are performed one 
needle at a time using an automatic seed after-loader called the seedSelectron (Nucletron)
49
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Fichtinger et al. have developed a 4 degrees of freedom (DoF) device, which 
stands vertically in the physical location of where a template would normally be placed. 
The device consists of two flat rectangular stages, each capable of motion in the 
ANTPOST and LEFTRIGHT directions. The first stage, referred to as the xy stage, 
mounts into a brachytherapy stepper as a template would, and controls the position of the 
front of the needle guide. The second stage, referred to as the ap stage, piggybacks on the 
first and controls the rear of the needle guide. The xy stage is capable of positioning a 
needle at the patients skin in a 4x4 cm work area, and the ap stage can move the rear of 
the needle ± 2 cm, allowing for needle angulation. Furthermore, the probe stepper 
position and angle are encoded for but not motor controlled. This group used a 
commercial treatment planning system, Interplant, which can instruct the robot to move 
the needle to template grid locations but cannot control the ap stage. Movement of the 
robot to non-template locations and control of the ap stage, and thus needle angulation, is 
done in a separate program (aka the Robot GUI). At the time of their publication, they 
were not yet able to create oblique plans using their software. Nonetheless, they have 
carried out several clinical template based implantations using their device.
Salcudean et al. 39 have developed a 4 DoF prototype, the Brachyguide, which has 
two linear sliding stages providing a 150x150 mm workspace and two stages providing 
angulation of ±30 °. Their device is not back-driveable, though the linear sliding stages 
can be controlled using cranks. They have reported on the sub-millimeter ANTPOST and 
LEFTRIGHT accuracies of seed deposition using parallel needles. At the time of their 
publication, the robot was controlled through an interface that allows for explicit text 
input of all four degrees of freedom (i.e. positions and angles). Like our system, the 
above two devices do not insert and deposit needles and seeds robotically.
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Yu and Podder et al. 40 have engineered a 16 DoF device mounted on a cart, with 
all DoF’s motor controlled (not back-driveable) except for two involving cart motion. It
is capable of motorized TRUS probe insertion, retraction, and angling, as well as needle
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positioning and seed insertions. It’s xy workspace is 6.2x6.7 cm  and can angle needles to 
a maximum of 10 °. This device completely replaces the standard brachytherapy hardware 
setup. All functions are motorized and operated through a cart mounted computer, or by 
using a wired remote “pendant” that has 10 buttons to control various DoF’s of the 
device.
Podder et al. have extended their design to develop a “multi-channel” device41. 
’’Multi-channel” refers to the fact that it performs the needle insertion and rotation, seed 
deposition, and needle retraction for multiple needles at a time, albeit without being able 
to angle them.
Bassan and Patel et al.42 have developed a cable assisted 5 DoF mechanism, coined 
as a ’’micro-manipulator” that is able to angle a needle with 2 DoF about a single remote 
centre of motion (RCM). It can also insert and rotate the needle and stylet. Positioning 
the needle’s tip (the RCM) above the patient’s skin is performed by a separate table 
mounted 4 DoF device developed by Yousef and Patel et al. 43. It is referred to as a 
macro-manipulator and it holds up the micro-manipulator. The probe is not directly 
coupled to these devices, however, which has led this group to also develop a stabilizing 
device with encoded joints to hold up the TRUS probe50.
Meltsner et al.51 have created a 6 DoF prototype that is capable of needle xy
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positioning over a very large workspace, and angling needles with a range of ±  30 
Needle insertion can be done automatically or manually. The robot can also rotate the 
needle cannula and stylet together or just rotate the cannula alone with the stylet 
stationary. The authors used their device to discover that increasing the rotational 
frequency of needles increased needle placement accuracy. At the same time, however, it 
also increased trauma to porcine gelatin phantoms due to the drilling nature of needle 
rotation 52.
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Lagerburg et al.53 have developed a device that inserts needles into the prostate by 
tapping the needle with a controlled amount of force. Their motivation stems from their 
observations that increasing the needle velocity (e.g. by tapping) decreases prostate 
motion and rotation44,54. Their concept relies on a traditional template based setup, using 
Nucletron’s FIRST sytem.
A needle translating and angling device has been presented by Hungr et al. 55. Their 
device consists of two translation rails for xy positioning, two small parallelograms for 
angling needles up to 30 °, an actuated rail and ball screw combination for needle 
insertion, and a small motorized needle rotation mechanism.
In summary, there are three main functions that can be performed by a mechatronic 
device in LDR PB: 1) needle positioning; 2) needle insertion; 3) and seed deposition. 
Some groups have developed devices that automate only the first function 38,39,36, others 
have automated all three 40_43,45, while others automated only the second 44 or the third 37. 
Motor control and/or encoding of the TRUS probe position and rotation is also an 
important function that some of the above devices perform 38’36’40>41’50
Almost all of these devices replace the brachytherapy template and act as needle 
guidance devices. They also vary greatly in their level of automation, degrees of freedom 
(i.e. ability to position oblique needles), physician interaction, complexity, size, weight, 
and ease of integration into the current brachytherapy setups. Additionally, these 
institutions vary in their approaches and state of development of software to plan, guide, 
and deliver brachytherapy treatments using their robotic devices. The following table is a 
summary of these characteristics for the various ultrasound guided brachytherapy devices 
found in literature.
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Table 1.2: Summary of characteristics of transrectal ultrasound guided
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§ N/A indicates that the information was not available (i.e. in literature)
*Uses planning software and stepper device from Interplant ® (at the time developed by 
Burdette Medical Systems Inc., Urbana-Champaign, IL)
fUses Variseed® (Varian Medical Systems Inc., Palo Alto, CA )
{Deposits all needles at the same time through a template
**Spot is the brachytherapy treatment planning system marketed by Nucletron
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1.9 Review o f Planning Studies
To date, no reports have been made in the literature of oblique needles being used in the 
planning of a clinical LDR PB case for delivery with a mechatronically assisted device. 
Nonetheless as mentioned above, experienced brachytherapists have reported on using 
oblique needles free-hand (e.g., with no template and no mechatronic assistance) in the 
operating room to avoid intraoperative PAI (i-PAI) .
To our knowledge, only two institutions have previously investigated the 
feasibility of oblique needles in dosimetric planning studies for LDR PB 33,34,3S. Both 
have implemented oblique needle inverse planning methods that have major limitations 
as will be discussed henceforth.
Fu et al. j3 initially proposed a conically shaped needle distribution pattern for 
robot assisted PB. All needles would enter through at most two pivot points at the 
perineum, and diverge towards the base. To generate their plans, they employed a genetic 
algorithm based inverse planning method, in which the search space of needles was 
limited by setting the pitch and yaw angles between needles to be constant. The constant 
angular intervals were set manually.
The same group later carried out another planning study, with mixing of oblique 
and parallel needles 34. They used three patient prostate segmentations and a constant 2D 
pubic arch shape, the vertical position of which was systematically changed by 1 mm to 
simulate varying degrees of PAI. They again limited the needle trajectory search space by 
forcing parallel needles through template positions, keeping the oblique needles angular 
separation constant, and avoiding the use of compound angle needles. Furthermore they 
limited the physical workspace through which needles could be inserted in order to 
customize the study for their robotic device. In this method, the angled needles were 
required to enter through common pivot points at the perineum, corresponding to 
template grid positions. As opposed to their conical method mentioned above, only two 
or three needles were made to enter through a common pivot point.
Van den Bosch et a l.35 also proposed the single and double conical needle pattern
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approach in a planning study. The have adapted a clinically proven template based LDR 
PB inverse planning simulated annealing (IPSA) algorithm developed by Pouliot et al.48 
and Lessard et al. 60,61 to an IPSA algorithm that uses oblique needles. Their algorithm 
employed no parallel needles, it discretized the angular separation between needles, and it 
also forced their needles through a common point (one or two) at the perineum.
The conical approaches presented above have the following limitations: 1) they 
fix all needle to diverge at the base, while concentrating them at the apex, which would 
create regions of high dose at the apex and low dose at the base j8; 2) inserting all needles 
though at most two points at the perineum would cause excessive trauma to a localized 
area '8. Finally, all aforementioned approaches, including the mixing of parallel and 
angled needles discretize the needle position, angle and spacing, thereby not truly taking 
full advantage of the freedom conferred by robotic assistance and the lack of a template. 
Moreover, the approaches were customized to the robotic devices in development at the 
institutions carrying out the planning studies. Thus the lessons learned from these studies 
are difficult to generalize for other brachytherapy devices and other institutions.
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1.10 Objectives
An oblique needle planning study that explores the benefits of oblique angles using non- 
discretized needle positions and angles is needed. Moreover, deliveries of clinically 
plausible oblique PB plans using a mechatronic device have not been done. Addressing 
these issues were the main objectives of this work, which has the following two parts:
1) Show in a planning study that LDR PB plans made using non-discretized 
oblique needle trajectories are more dosimetrically optimal than those using 
parallel trajectories for large prostates and PAI.
2) Test in a phantom study, the feasibility and accuracy of delivering oblique 
plans for large prostates and PAI using our mechatronic device.
1.11 Thesis overview
The first chapter contains introductory material describing prostate brachytherapy, the 
motivation for using mechatronics and 3D TRUS guidance for delivering oblique 
needles, as well as statements of the thesis objectives, as seen above.
The second chapter is a modified version of a manuscript submitted on March 9th, 
2011, to the International Journal of Radiation Oncology, Biology, Physics based on our 
work. A decision on its acceptance is still pending as of April 25th, 2011. The manuscript 
consists of two main parts, a planning study followed by a phantom study, corresponding 
to the two objectives of this thesis. The planning study involved comparing parallel 
needle template (PT) based planning to two different types of planning methods 
unrestricted by the template, parallel needle non template based (PNT) plans and oblique 
needle (OBL) plans. To our knowledge a suitable oblique needle LDR PB inverse 
planning method that uses arbitrary non-discretized needle positions and angles does not 
exist. Thus the plans were manually created. Plans were evaluated and compared based 
on how well they met recommended dosimetric parameters (see Table 1.1 on page 15)
The planning study had two parts. The first involved increasing the volume of a 
prostate from 45 to 80 cc, while keeping the pubic arch size and position constant, and
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investigating the effects of the different planning methods on dosimetric parameters 
(Table 1.1 on page 15). The second planning study, called the constant volume planning 
study, involved five subject prostates that were all enlarged to 60 cc, while keeping the 
pubic arch size and position constant.
The phantom study of Chapter Two involved delivering an oblique plan to a 
prostate phantom. The phantom construction was unique for two main reasons. Firstly, 
the minimum pubic arch opening was simulated with a plate that replicated the subject’s 
pubic arch as a 2D projection to a transverse plane situated at the apex of the prostate. 
Secondly, it mimicked the dimensions, positions, and orientations of the prostate, pubic 
arch, and TRUS probe of the 60 cc prostate subject in the planning study that had the 
most pubic arch interference. To our knowledge, replicating organ surfaces and using an 
artificial pubic arch has not been done before in a phantom study.
The final and third chapter discusses the limitations of this work, potential 
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Chapter 2
2 Prostate brachytherapy with oblique needles to treat large 
glands with pubic arch interference*
2.1 Introduction
In this chapter, we report on a study consisting of dose planning, followed by an oblique 
plan delivery in a phantom. The dose planning study aimed to show that LDR PB plans 
using non discretized oblique needle trajectories are more dosimetrically optimal than 
parallel trajectories for large prostates with PAI, irrespective of device or software 
design. The phantom study aimed to test the feasibility of delivering an oblique plan for a 
60 cc prostate with PAI using our mechatronic device providing preliminary accuracy 
results.
2.2 Methods and Materials
2.2.1 Planning Study
3D TRUS images from five subjects were chosen from a set of 3D TRUS images taken at 
the London Health Sciences Centre, University Hospital at the University of Western 
Ontario. They were chosen based on their urethras and prostates being clearly visible for 
segmentation and the original prostate volumes and PAI’s being less than 60 cc and 1 cm, 
respectively. For one patient, the prostate was systematically enlarged from 40 cc to 80 cc 
in steps of 5-10 cc. For all five patients, the prostate was artificially enlarged to 60 cc for 
further planning studies. Three different LDR PB plans were generated for all the prostate 
volumes: parallel template (PT), parallel no-template (PNT), and oblique (OBL) needle
*
Chapter 2 is a modified version of the manuscript that has been submitted to the International Journal of 
Radiation Oncology * Biology * Physics on March 9th, 2011.
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plans. The constraints on prostate size and PAI in patient selection were designed to 
exclude excessively large prostates and PAI’s that would cause all plans on enlarged 
prostates to fail and thus make it difficult to investigate the benefits of oblique needles.
2.2.2 Volume Segmentation
The prostate, rectum, pubic arch, and urethra in the 3D TRUS images were segmented 
using a semi-automated segmentation method I 2’3’4. The basic outline of a urethra is 
sometimes visible in 3D TRUS even without a catheter, which was true for the subject 
images selected for this study. The pubic arch was simplified to be the smallest 2D (in the 
ANTPOST-LEFTRIGHT plane) pubic arch opening, and its SUPINF position was set to 
the most inferior position of the prostate.
Wallner e t  a l. 4 and Bellon e t  ah  5 have shown that prostate volumes and PAI’s 
are not well correlated and that PAI is highly variable. Since we aimed to plan on large 
prostates with PAI, we controlled prostate sizes by enlarging the segmented prostates to 
specific known sizes. A large study by Collins e t ah  6 on ultrasonically determined 
patterns of prostate enlargement due to benign prostatic hyperplasia (BPH) found that 
between patients with prostates < 20 cc and > 50 cc, the overall difference to the 
prostate’s maximum anterior/posterior (ANTPOST), superior/inferior (SUPINF), and 
left/right (LEFTRIGHT) dimensions had the ratio of 77:50:36. The prostate ANTPOST, 
SUPINF, and LEFTRIGHT dimensions were thus enlarged by the factors 0.77A, 0.50A,
0.36A, respectively. Given a desired volume, the scaling factor A was optimized using the 
fm in se a rc h  function (a non-linear optimization method based on the simplex algorithm 7) 
in Matlab (The Mathworks Inc., Natick, MA). Figure 2.1 shows the original 3D TRUS 
volumes and segmentations for Subject #1 and #5, as well as the boundaries after 
enlarging their prostates (shown in purple) to 60 cc.
A conservative approach was taken to change the urethra’s dimension, in which 
the urethra (shown in gold in Figure 2.1) was changed only in the SUPINF direction to 
match the change in SUPINF length of the prostate. Also, its position with respect to the 
middle of the prostate was maintained. The positions and sizes of the rectum (shown in 
pink) and pubic arch (shown in orange) were not changed, and the distance between the
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prostate’s posterior edge and the rectum was held constant. Finally, following the 
European Society of Therapeutic Radiology and Oncology (ESTRO) guidelines for LDR 
PB 7, the planning target volume (PTV) was generated with a 3 mm maximum treatment 
margin added everywhere around the prostate but kept to 0 mm at the base and 
posteriorly.
Figure 2.1: 3D TRUS volumes and segmentations before and after prostate 
enlargement to 60 cc. Subject #1 and #5 had the second lowest and greatest Pubic 
Arch Interference (PAI) encountered in this study, respectively. Prostate is purple, 
PTV is turquoise, urethra is gold, rectum is pink, and pubic arch is orange.
2.2.3 Plan types and criteria
Three different types of LDR PB plans were generated: parallel template (PT) plans, 
parallel no-template (PNT) plans, and oblique (OBL) plans. PT plans used the traditional 
0.5 cm spaced grid, with all needles being parallel. PNT plans did not use a template and
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its needles were freely translated in the ANTPOST - LEFTRIGHT plane but not rotated. 
They were generated by removing the template and using the PT plans as a starting point. 
Finally, OBL plans were generated by adapting the PNT plans. Oblique plans used no 
template and its needles were translated as well as rotated to overcome PAI. All needles 
were required to pass under the 2D pubic arch positioned at the prostate apex. Also, 
oblique needle angles were limited to < 15° since needles at greater angles cannot be seen 
under US guidance. Furthermore, angling needles down towards the prostate’s posterior 
were prohibited due to the practical danger of piercing the rectum during LDR PB.
The planning study required strict and definitive metrics for quantifying the 
quality of the LDR PB plans. ESTRO dose volume histogram (DVH) recommendations
o
for LDR PB were used for this purpose , except that a more stringent requirement of 
limiting the prostatic urethral dose between 100% and 120% of the prescription dose (Rx) 
was implemented as opposed to ESTRO’s recommended range of 100% to 150% Rx. 
This was done in reflection of the urethral constraints employed at the London Regional 
Cancer Program, which the authors believe is more ideal for the urethra, despite being 
harder to achieve. Our seed choice was Iodine-125 (1-125), and thus the TG-43 
prescription (Rx) dose to the PTV of 145 Gy 9 was used. In summary, the DVH indices 
considered to evaluate the LDR PB plans and their corresponding passing criteria are 
specified in Table 2.3 (page 55), as well as in Table 1.1 (page 15). An additional metric, 
PTV VI00 / #seeds (cc/seed) was also computed to measure the efficiency of a treatment 
plan. PAI was also calculated in terms of volume and area, as the volume or maximum 
overlap area obstructed by the pubic arch and thus unavailable to parallel needles.
43
Figure 2.2: The three types of plans generated, shown for Subject #5: parallel 
template (a), parallel no-template (b), and oblique (c). The left and middle columns 
show sagittal and axial slices, respectively. The right column shows axial slices of 
the simplified 2D pubic arch (in blue) at the apex of the prostate.
2.2.4 Increasing Volume Planning Study
Two types of planning studies were carried out. In the first planning study, the prostate of 
a single subject (Subject #1), with a volume of 39 cc, was systematically increased to 40,
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50, 60, 65, 70, 75, and 80 cc. For each volume the three different types of previously 
mentioned plans were generated, unless it was clearly evident that the plan would have 
failed the ESTRO criteria. This served to show how the DVH indices changed as prostate 
size increased while the pubic arch size remained unchanged.
2.2.5 Constant 60 cc Volume Planning Study
In the second planning study, the three types of plans were again generated for all 
five subjects, while increasing their prostate sizes to 60 cc (n = 5). 60 cc was chosen as 
the volume of interest due to it being the upper end of the recommended clinical limit or 
20% larger than the common limit of 50 cc. Finally, each DVH index (or other metric) 
was grouped by plan type, and averaged across all 60 cc prostate subjects. The mean 
value of each metric of PT plans was compared to those of PNT plans and to OBL plans. 
Paired one sided t-tests were performed to examine if PNT and OBL plan metrics were 
deemed significantly better (i.e. higher or lower) than those of PT plans. Changes in plan 
metrics were deemed significant if the /?-value was less than 0.05.
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2.2.6 Phantom Study
Figure 2.3: Stages of making an agar phantom, (a) The 60 cc negative mould; (b) 
tungsten prostate phantom is positioned in a compound angle plate using a mould 
half; (c) tungsten prostate in compound angle plate; (d) prostate is encased in a 
sphere and fiducials are placed (e) upper half of phantom is poured with the plate 
on risers; (f) plate is removed and the pubic arch is placed for the final pour of agar.
The primary aim of the phantom study was to demonstrate the feasibility of delivering the 
oblique plan on a 60 cc agar prostate phantom, using the subject geometry with the 
greatest PAI (Subject #5), i.e. the most difficult 60 cc case encountered during the 
planning study. A custom phantom (seen in Figure 2.3) was designed and built in our lab. 
The surface of the 60 cc prostate was imported into 3D CAD software (SolidWorks by 
Dassault Systemes SolidWorks Corp., Concord, MA), and a negative mould was 
produced using rapid prototyping (Figure 2.3a). The segmentation of the subject’s pubic 
arch was also imported to CAD software and machined. A compound angle plate and 
risers were designed to position the prostate mould within the phantom container to
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preserve the relative geometry and orientation of the prostate, pubic arch, and probe 
location (Figure 2.3b,c,e,f). Steel ball bearings of 1.5 mm diameter were placed in the 
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Figure 2.4: The treatment system. The device’s front and back arms are locked in 
position with friction brakes. The needle can be guided with the aid of real time 
visual feedback of the needle’s intended and actual trajectory. This can be done 
using the transverse transducer (as shown above) or using the sagittal transducer.
The prostate and background were made using a mixture of agar (3% by weight), 
water, and glycerol (7% by weight) to mimic the average speed of sound in tissue of 1540 
m/s 10. Cellulose powder (10 % by weight) was added to the background mixture to 
generate ultrasound contrast relative to the prostate. 10 g/L of Tungsten powder was 
added to the prostate mixture to give contrast under CT imaging.
Bevelled needles (Bard® BrachyStar® 18 guagex20 cm length) were preloaded 
with their seed trains using spacers cut from 0.9 mm diameter nylon fishing line and 
dummy 1-125 seeds. Seeds had a length of 4.43 mm and the fishing line spacers were
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manually cut as best as possible to their intended lengths (i.e. i5 + 0.07 mm, i = 1, 2...9) 
and measured using a Vernier caliper. Spacers measuring less or more than 0.01 mm of 
their intended lengths were not used.
The details of the mechatronic device (see Figure 2.4) designs are given by Bax e t  
a l. 11 and its operation is summarized here. The needle positioning arms shown in Figure
2.4 are simple to manually control with the use of spherical linkages to create a remote 
center of motion (RCM), and the visual overlays of the intended and actual needle 
trajectories by the treatment system (see Figure 2.5). The system visually guides the 
physician to adjust the needle entry point within a 6 cm square workspace at the skin with 
2 DoF’s using the front positioning arm. Locking the front arm mechanically constrains 
the needle to pivot in space about the needle’s entry point at the skin (the RCM) with at
most 30° angulation. Finalizing the needle trajectory is done by positioning the rear arm, 
which is also visually guided. With both arms locked, a needle can be inserted through 
the needle guide. The needle guidance interface is shown in Figure 2.5.
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Figure 2.5: Visual guidance interface for mechatronic device arms and needle 
insertions. Yellow cross hair, circle, and needle outline (in the sagittal view) indicate 
the real time position of the front arm, back arm, and needle trajectory, 
respectively. The physician’s task is to line them up to their intended positions, 
indicated by the magenta cross hair, circle, and needle outline.
During manual needle insertion, the ultrasound probe was automatically rotated 
repeatedly about a small angle to update the 3D TRUS volume with the near real time 
position of the actual needle. At the medium probe rotation speed, it takes approximately
1 sec for the probe to be rotated 15 ° (i.e. to image a 15° yaw needle) in one direction (i.e. 
half a rotation cycle), and the 3D TRUS image cube to be updated, which occurs every
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half rotation cycle. The transverse, coronal, and sagittal plane slices, from the 3D volume, 
coincident with the intended needle position (the transverse view was set to an arbitrary 
depth along the needle) were displayed simultaneously. Intended needle and seed 
positions, as well as a near real time automatic needle segmentation were overlaid onto 
the 3D TRUS image displays for guidance 12 (see Figure 2.5).
The plan delivery was performed with a marker placed on each needle to indicate 
its intended insertion depth. Needle guidance, insertions, and seed deposition were done 
one needle at a time. Following the delivery of the plan, the phantom was imaged with 
CT (Phillips Brilliance Big Bore). The US image and CT image are designated as (Ius) 
and (ICT), respectively.
The agar prostate phantom was encased in a 60 mm diameter sphere of agar, as 
shown in Figure 2.3 (d), and fiducials were embedded on the surface of the sphere as 
evenly as possible. The total number of fiducials that were visible under 3D TRUS was 
Nf = 22. Others were not imaged due to the limited length of the sagittal crystal (60 mm),
and rotation of the probe mover (90°). Locations of the ith fiducial in US, f lu s , and CT, 
f c r , (i = 1, 2, 3... N f, N f =  22), were used to register the ultrasound image, Ius, to the CT 
image, I c t - The rigid registration transformation matrix, T , was found by using the 
fm in s e a rc h  function, which minimized the fiducial registration error (FRE), defined as 12,
FRE  = )VW II f c T - f u s f  
i N f
( 1)
Since the actual seed positions are difficult to accurately locate in US due to 
image speckle and lack of contrast, we used CT imaging to localize the actual seed 
positions, P ep  =  (Pcrx> VcTy>Vcrz)> which we compared to their intended and pre­
planned post-registration US seed positions, p us = (pusx> Vusy> P u sz)• Seed deposition 
accuracy was analyzed by computing the Seed Targeting Errors (STE) of the i ,h seed, 
S T E l , which is the signed vector difference between the i ,h actual seed location, p lCT, and 
the registered intended seed location, p lu s . The signed mean STE, was computed for each
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of the three cartesian component to determine the directional bias of seed deposition. The 
signed mean STE, and their components are defined as
S T E  =  (STEXfSTEyfSTEz) (2)
Ns Ns
V  S T E 1 = y Pcr ~  P u s
L  n s L  n s
1=1 1=1
N*





where, j  =  x , y , z  corresponds to the SUPINF, ANTPOST, and LEFTRIGHT 
directions respectively. N s is the number of seeds deposited. The distance, d \  between 
each i lh actual and intended seed position and the mean distance, d, were computed as
dl = \\Pct -  PusII
NsJ  v  \\Pcr -  Pus ||d = L—ws—¿ = 1 (5)(6)
N s was 121 in the phantom study preplan but due to a seed being stuck to the stylet and 
being pulled out, N s was reduced to 120 post delivery.
Errors in manual seed deposition along the needle's trajectory, is independant 
from the errors in the needle trajectory, which is primarily dependant on the mechatronic 
device and software. Approximations of the actual needle trajectories were found by 
fitting a 3D line to the actual seed positions of each needle using singular value 
decomposition. This allowed decoupling the actual seed deposition depth and needle 




2.3.1.1 Increasing Volume Planning Study
The different volumes of Subject #1, the corresponding PTV volume, and the volume of 
prostate obstructed by PAI (PAI volume) are shown in Table 2.1. PT and PNT plans were 
manually generated for prostate volumes up to and including 60 cc and 65 cc, 
respectively, due to it being apparent that these planning methods would not achieve the 
DVH objectives for greater volumes. OBL plans were generated for volumes up to and 
including 80 cc. The prostatic urethra DVH criteria (Table 2.3) was adhered to as strictly 
as possible. This resulted in all plans having constant urethral VI00 and VI20 values 
near 100% and 0%. Rectal doses were also well within the recommended ranges. The 
only plan quality metrics that distinguished PT, PNT, and OBL plans, however, were 
PTV VI00, and PTV V100/#seeds, which are shown in Figure 2.6.
Figure 2.6(a) shows that for Subject #1 ’s anatomy, the maximum prostate volume 
that can be planned on using PT and PNT methods was between 60 cc and 65 cc. Table
2.1 shows that the corresponding PAI volumes are 6 cc and 8 cc. The maximum prostate 
volume that can be planned using OBL needles was between 75 cc and 80 cc, with the 
corresponding PAI volume being 13 cc and 16 cc, as shown in Figure 2.6 (a) and Table 
2. 1.
Table 2.1: Prostate, PTV, and PAI volumes of Subject #1.
Prostate Volume (cc) 40 50 60 65 70 75 80
PTV Volume (cc) 54 68 78 84 89 95 101
PAI Volume (cc) 0 2 6 8 11 13 16
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Figure 2.6: Subject #1 PTV V100 and PTV V100/#seeds versus prostate volume for 
Parallel Template (PT), Parallel No Template (PNT), and Oblique (OBL) plans.
2.3.1.2 Constant 60 cc Volume Planning Study
For the 60 cc planning study, the amount of PAI by volume and area are shown for each 
of the five subjects in Table 2.2. The DVH curves for their PTV, prostate, urethra, and 
rectum for the three different types of plans (PT, PNT, and OBL) are shown in Figure 2.7 
for Subject #1 and #5. PT and PNT plans both passed for two subjects with the lowest 
PAI (Subjects #1 and #2), and OBL plans passed for all five subjects, as shown in the last 
row of Table 2.3.
As can be seen in Figure 2.7, the low PAI of subject 1 has resulted in all three 
types of plans (PT, PNT, OBL) passing the ESTRO criteria and having similar DVH 
curves for the organs. For subject 5 that has high PAI, however, only the oblique plan 
passed, while the two parallel type plans had very similar DVH curves (Figure 2.7(b)).
The /?-value results of the paired one sided t-tests of the mean DVH indices 
(averaged across all five subjects) between parallel template (PT) and parallel no­
template plans (PNT), and parallel template and oblique (OBL) plans are shown in Table 
2.3. As can be seen from the significant /5-values (< 0.05) in Table 2.3, which are bolded
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and marked with daggers, the PNT technique showed a significant improvement for only 
the PTV VI00 at the 5% significance level. The OBL technique, however, showed a 
significant improvement for all organs at the 5% significance level. Additionally, the 
OBL plans had a significantly higher value of PTV coverage per seed.
Table 2.2: Pubic Arch Interference (PAI) for all subjects’ prostates that were 
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(b) Subjecl #5 showing high PAI
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Figure 2.7: DVH curves for Subject #1 (a) and #5 (b) that show low and high pubic 
arch interferences (PAI), respectively. Both prostates were 60 cc. High PAI 
exhibited by Subject #5 resulted in both parallel methods (blue and green) 
underdosing the PTV (solid line).
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Table 2.3: Planning Study results for the constant 60 cc volume study. *
Criteria Mean (standard error) P - value
PT PNT OBL PNT- OBL-
PT PT
PTV
V I00 (%) > 95% 87.7 (3.2) 90 (3.1) 97 (0.4) 0.010f 0.016f
V I50 (%) < 50% 40.5(1.6) 39.6(1.0) 41.8(1.1) 0.298 0.277
V200 (%) - 17(0.5) 16.7 (0.4) 17.1 (0.8) 0.355 0.454
D90 (Gy) > 100% Rx 133.4(11.5) 138.7(10.5) 159.9(1.0) 0.104 0.035f
Urethra
V I00 (%) 100% 96(1.9) 97.3(1.5) 99.3 (0.3) 0.132 0.087
V I20 (%) 0% 0.1 (0.1) 0.1 (0.1) 0 (0.0) 0.411 0.16
D30(Gy) < 130% 164(1.0) 162.6(1.5) 160.1 (1.7) 0.121 0.044+
= 188.5 Gy
DIO (Gy) < 150% 166 (0.8) 164.7(1.4) 162.8(1.6) 0.103 0.043f
= 217.5 Gy
Rectum
R100 (cc) < lcc 0.2 (0.1) 0.2 (0.1) 0.1 (0.0) 0.173 0.016r
D2cc (Gy) <= 145 Gy 105 (5.1) 104.8(4.8) 101 (5.6) 0.421 0.010+
DO.lcc (Gy) < 200 Gy 151.4 (3.8) 148.3 (4.1) 143 (4.7) 0.188 0.0331
PTV VI00 /#seeds 0.6 (0.0) 0.6 (0.0) 0.7 (0.0) 0.069 © © © —
H
(cc/seeds)
#needles 26.6(1.2) 24.2 (0.4) 25.4 (0.6) 0.040t 0.201
#seeds 114(3.3) 115.4 (2.7) 118(1.6) 0.175 0.203
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Number of successful 2 2 5
cases out of five subjects
Abbreviations: PT = Parallel template plan; PNT = Parallel non template plan; OBL = Oblique 
plan
*Mean value of metrics, grouped by plan type: PT, PNT, OBL. Standard errors are in brackets to 
the right of the mean. P -values are shown from paired one sided Student T-test results. PNT-PT 
and OBL-PT represent comparisons between PT means with PNT and OBL means, respectively. 
Also shown are the DVH index criteria as well as number of needles and seeds used.
Significant p-values (p  <  0.05).
2.3.2 Phantom Study
The signed mean displacement between the CT fiducial locations, f lCT, and the post 
registration US fiducial locations, f lus, was (0.039, 0.051, 0.049) mm. The FRE (equation 
1) was found to be 0.79 mm. The post registration overlay of the pre-plan on the CT 
image of the phantom is shown in Figure 2.8. The STE results from the oblique plan 
delivery to subject 5’s 60 cc anatomy are shown in Table 2.4.
Histograms of the # seeds versus the distances, d\ and displacement, STE, of seed 
positions are shown in Figure 2.9. Certain seeds had large depth errors due to being 
pulled out, by suction for example, during needle and stylet extraction, and this affected 
their ant/post and left/right errors. The seeds, for which SUPINF displacement error was 
greater than 95% confidence interval about the mean SUPINF position, are shown in 
black and dark grey.
3D lines were fitted to the actual seed positions to approximate the actual needle 
trajectory as previously mentioned. The seeds were translated, along their approximate 
actual needle trajectory, to their intended depth. Finally, the ant/post, and left/right 
displacements were recalculated for these depth corrected seeds, to observe seed 
trajectory error without depth error (see Figure 2.9(e-f)).
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Figure 2.8: An overlay of the registered preplan on a sagittal CT slice of the 
phantom. The seeds are bright ellipsoids, while the fiducials are circular.
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Table 2.4: Seed Targeting Error. N = 120. Depth corrected SUPINF error is 0 ± 0
mm.
Mean (mm) Standard Deviation (mm)
A SUPINF 0.9 2.7
A ANTPOST -0.4 1.0
A LEFTRIGHT 0.2 1.2
|A SUPINF | 2.0 2.1
|A ANTPOST | 0.9 0.6
|A LEFTRIGHT | 0.9 0.8
Distance 2.6 2.1
DEPTH CORRECTED
A ANTPOST -0.53 0.93
A LEFTRIGHT 0.21 1.07
|A ANTPOST | 0.89 0.59
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Figure 2.9: Histograms of #seeds versus distance and displacement between 




In both planning studies, the limiting DVH indices that lead to any under-dosing of the 
PTV for larger PAI’s were the stringent requirements of keeping the prostatic urethral 
dose between 100% and 120% Rx as much as possible. Dose can be increased to the 
antero-lateral part of the prostate for cases of large PAI in a few ways but was not done if 
it caused the prostatic urethral dose constraints to be exceeded. For plans with parallel 
trajectories (PT and PNT plans), more needles and seeds can be placed throughout the 
prostate to increase low dose spillage into the overlap volume, as well as by preferentially 
increasing the density of needle and seeds along the PA edge, directly below the volume 
of overlap. Adapting PT plans to PNT plans allowed removing some needles and 
spreading others out to make more efficient use of space within the prostate, and 
adjusting the seed loading configurations within the needles. Thus, PNT plans used 
significantly fewer needles on average than PT plans (Table 2.3). Adapting PNT plans to 
OBL plans involved angling needles near the pubic arch into the overlap volume. This 
initially creates low dose regions at the base of the prostate, which is remedied by adding 
one or two more needles and loading them with seeds. This explains why OBL plans used 
more needles on average than PNT plans (Table 2.3). Finally, adjustments are made to 
needle positions/angles, and seed loading to increase symmetry, homogeneity, PTV 
coverage, and urethral/rectal sparing.
A correlation exists between PTV V I00, PTV V I50, Urethral VI00 and VI20, 
and the number of seeds outside the prostate. The difficulty with increasing PTV V I00 is 
that it can also increase PTV V I50 and Urethral VI20 close to or past their upper limits. 
An easy way to overcome this is by placing seeds outside the prostate. However, this is 
not a good planning technique, especially for loose seed implants, and its use was limited 
as best as possible. This challenge presented itself most often when attempting to achieve 
coverage at the base and apex. Qualitatively, it was noticed that PT plans had the most 
seeds outside the prostate, and OBL plans had the fewest. For future work, it would be 
beneficial to quantify the number of seeds outside the prostate if any as an additional
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quality indicator of LDR PB plans.
2.4.1.1 Increasing Volume Study with Subject #1
Since the increasing volume study had only a sample size of one, it did not have the 
statistical power to answer the question of what the upper limit of PAI is that can be 
overcome by the three different LDR PB planning methods. An upper limit of PAI, 
therefore, cannot be suggested from this study. Nonetheless, it can be inferred that OBL 
plans are better than parallel plans at achieving PTV coverage as PAI increases due to 
increasing prostate volume (Figure 2.6(a)); and, that the PNT planning method is only 
slightly better than the PT method at using each seed more efficiently to achieve 
coverage, while the OBL method is more efficient than the other two. The latter point is 
shown by the PTV V100/#seeds metric versus prostate volume graph (Figure 2.6 (b)).
2.4.1.2 Constant 60 cc Volume Planning Study with all Five Subjects
Parallel type plans (PT and PNT) each only passed the DVH index criteria for the same 
two subjects that had the lowest PAI. On average, their VI00 and D90 values did not 
meet their minimum criteria of being >95% and >100% Rx, respectively. Despite this 
similarity, PNT plans had one metric that was significantly better than PT plans, the PTV 
V I00 (p=0.010). The absence of a grid may confer better PTV coverage for PNT plans 
compared to PT plans, but parallel needle trajectories simply could not overcome the 
larger PAI’s encountered in this study.
2.4.2 60 cc Phantom Study for Subject 5
2.4.2.1 Fiducial Registration Error
The reason for placing the fiducials on a spherical agar shell around the agar prostate (see 
Figure 2.3) was motivated by work by Fitzpatrick e t a l . It can be shown that our 
measurements of seed targeting error is analogous to what Fitzpatrick e t a l. refer to as 
Target Registration error (TRE) (i.e. displacement between homologous points other than 
fiducials). More importantly, TRE (and likewise STE) is dependent on fiducial
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orientation and distribution 13. The TRE is proportional to the FLE and the distance of 
targets to the fiducials' centroid ( / cr); as well as being inversely porportional to f
and the distance of fiducials to their centroid. This implies that targets should ideally be 
closer to f CT than the fiducials themselves, and that fiducials should ideally be evenly 
spaced and equidistant from f CT.
2.4.2.2 Seed Placement Error
There are two major independent sources of error in the seed positions seen in the 
histograms of Figure 2.9. The first is due to needle trajectory guidance errors, which 
primarily affects the ANTPOST and LEFTRIGHT errors. The second is due to errors in 
manual seed deposition along the inserted needle’s trajectory, which primarily affects 
SUPINF error. For oblique needles, however, large seed depth errors along the needle 
trajectory may add to errors in the ANTPOST and LEFTRIGHT directions.
Suction or adhesion to the stylet by bone wax was a source of extreme SUPINF 
error. Besides a single seed that was entirely pulled out, there were five seeds that were 
outside the 95% confidence interval for SUPINF displacement (Figure 2.9(b)); one 
(black) from a two seed needle and four (dark grey) from a six seed needle. The black 
seed’s distance error is dominated by its SUPINF error, while the dark grey seeds’ errors 
are a combination of trajectory error and SUPINF placement error.
When the SUPINF error was decoupled from the ANTPOST and LEFTRIGTH 
error, the spread in ANTPOST and LEFTRIGHT displacements both decreased. The 
mean ANTPOST and LEFTRIGHT displacements, however, increased. This was because 
the outlier seeds were brought closer to their intended ANTPOST and LEFTRIGHT 
positions, which caused the observed shift in the mean ANTPOST and LEFTRIGHT 
displacements.
During needle insertion, needle trajectories may have been misguided due to low 
visibility under US, which can be a problem if needles are angled. Angling the needle’s 
pitch causes the acoustic waves to deflect away and not fully return to the transducer, 
thereby decreasing the contrast of the needle. High yaw angles results in the sagittal
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acoustic waves only imaging a portion of the needles at a time, forcing the probe to be 
rotated to observe the needle’s bevel and its full trajectory. These sources of trajectory 
errors have resulted in the spread and standard deviation being larger for the 
LEFTRIGHT displacement than for the ANTPOST displacement, as shown by Figure 
2.9(c-d) and Table 2.4. This may be explained by the sagittal transducer being used 
exclusively. Due to its high temporal resolution, the live sagittal view clearly shows the 
ANTPOST trajectory of the bevel even with high pitch and yaw angles, while the 
needle’s LEFTRIGHT position is not readily apparent.
Nonetheless, the needle’s ANTPOST and LEFTRIGHT trajectory could be 
tracked for high yaw angles using 3D US reconstructions. However, the limitation of the 
3D US reconstruction is that it is not done real time due to computational burden. There 
are also stair-casing effects in the cube view, depending on how the image is sliced for 
viewing.
2.4.3 Mechatronic Device Design
Almost all of the aforementioned mechatronic devices reported in the literature 10,13-22 
replaces the brachytherapy template and act as needle guidance devices. They also vary 
greatly in their level of automation, degrees of freedom (i.e. ability to position oblique 
needles), physician interaction, complexity, size, weight, and ease of integration into the 
current brachytherapy setups.
We have employed a non-motorized version here. Its small footprint is minimally 
intrusive to the physician’s workspace. Despite its lack of an automatic needle insertion 
device, it can easily be made compatible with the Mick applicator or the Seed Selectron. 
Plans have been made to test both afterloaders, which may also help improve the seed 
depth accuracy.
2.5 Conclusion
Compared to parallel template based planning methods, the oblique planning method had 
significant benefits for PTV coverage and sparing of critical organs (urethra, rectum),
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whereas the parallel non template based method was only significantly beneficial for the 
PTV coverage. Both parallel non template and oblique planning methods made more 
efficient use of seeds in providing coverage to the PTV. However, only the oblique plans 
were able to overcome large pubic arch interference.
An oblique plan was successfully delivered to a 60 cc phantom with large pubic 
arch interference using our mechatronic device and 3D TRUS guidance software. Seed 
placement error (displacement from intended locations) was sub-millimeter in all 
directions, with superior-inferior error being the largest. This study demonstrated the 
benefit and feasibility of prostate brachytherapy with oblique needles to accurately treat 
large glands obstructed by pubic arch interference (up to 1.3 cm).
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Chapter 3
3 Conclusion and Future Work
The two objectives stated in chapter 1 of this work were achieved. In summary, the 
planning study showed oblique needle plans were significantly better than parallel needle 
template based plans for larger glands with pubic arch interference (PAI). Preliminary 
phantom results showed that an oblique plan for a large prostate with large PAI can be 
delivered accurately using a mechatronic system and 3D TRUS guidance.
What made the planning study unique is that it utilized oblique needles with 
arbitrary positions and angles, which were not discretized nor limited to the constraints of 
a specific mechatronic device design. The phantom study was unique in being the first to 
deliver an oblique plan to a phantom that realistically replicated the shape of a patient’s 
anatomy. Mimicking the shape of a large prostate (60 cc) with large pubic arch 
interference (PAI) was crucial to testing the feasibility of accurately delivering an oblique 
plan for patients with such anatomy. This was an important step towards achieving the 
main clinical motivation of this work, which was to use LDR PB to accurately treat 
patients with larger glands and PAI that are not normally offered the procedure, or are 
required to first undergo hormonal downsizing.
It is difficult to quantitatively predict what percentage of men with prostate cancer 
(PCa) can potentially benefit from this work. Studies that report the frequency of PAI 
occurrence only do so amongst a subset of men that were already screened for low dose 
rate prostate brachytherapy. Moreover, some physicians may not discuss LDR PB as an 
option for potential candidates. One possible way to estimate what percentage of men 
with PCa may benefit from this work is to review studies in which patients were 
considered for brachytherapy but first given androgen deprivation therapy (ADT) to 
downsize their prostate. The number of patients receiving ADT for brachytherapy 
compared to the total number of patients that received brachytherapy in such a study may 
shed some light on what percentage of men may benefit from this work. Still, such a
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study may not include men with very large prostates that may benefit from using oblique 
needles, if their prostate sizes were deemed too large even for hormonal downsizing for 
brachytherapy.
The reason that this work has not been done previously may be due to technical 
limitations of developing software to plan and deliver oblique needles. Extensive work 
has been previously done by our lab to develop a planning system that allows one to 
create manual plans without the use of a template, using needles of arbitrary positions 
and angles. Although some institutions have mechatronic devices that are capable of 
oblique non template positions, they may not have the software capability to create 
suitable oblique plans and deliver them.
Further phantom study work needs to be done, however, to better demonstrate the 
practical feasibility of delivering oblique plans. An outline of the manual planning 
techniques used to adapt template based plans to parallel non-template plans, and further 
adapting these plans to oblique plans will be discussed. Then, limitations in both the 
planning and phantom studies that have not been addressed in chapter two will be 
addressed below. This will be followed by a presentation of ideas for future work.
3.1 Limitations o f the planning study
No statistical analysis could be done on the increasing volume planning study because 
only one subject was used. Although statistical significance was found for the constant 
volume planning study, the sample size was small (N = 5). Nonetheless, the observations 
that DVH indices are better for OBL plans than PT plans would be expected with 
additional subjects. Therefore increasing the sample size would likely result in more 
significance being observed.
The outcomes of the planning study may also have been different if the original 
ESTRO upper prostatic urethral dose limit of keeping VI50 < 0 % was used instead of 
keeping VI20 < 0 %. Keeping urethral VI20 < 0 % as well as limiting the number and
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distance of seeds outside the prostate made it difficult to maintain coverage to the base 
and apex. There may have been more successful cases of parallel trajectory plans (PT and 
PNT) if the less stringent upper urethral dose limit of keeping VI50 < 0 %  was used. All 
OBL cases were already successful with the more stringent DVH requirement.
The results show that oblique planning leads to more dosimetrically optimal plans 
than parallel methods. However, the fact that the plans were generated manually makes 
the results difficult to reproduce in exactly the same way. For example, many different 
needle and seed positions can satisfy the ESTRO DVH conditions. In fact, one can 
potentially place many seeds far outside the prostate to create a very homogeneous dose 
distribution within the PTV, and meet all the ESTRO DVH criteria. This is because dose 
constraints do not yet exist for adjacent tissue, except the rectum. Constraints are needed 
for the potentially critical adjacent organs such as the nerve bundles surrounding the 
prostate and the penile bulb. Constraints also do not presently exist for other adjacent 
tissues, such as the muscular bladder neck, bladder wall, and surrounding muscles. One 
may potentially constrain the dose and number of seeds outside the prostate by 
quantifying the number of seeds outside of the prostate, and their distances to the 
prostate. The exact method of quantifying and constraining it, however, needs to be 
determined.
Another way of constraining high doses outside the prostate can be to employ the 
PTV VI00 / #seeds metric, previously mentioned as a way of quantifying the efficiency 
of a dose plan. For a given prostate volume, a manual planner can strive for maximum 
efficiency while varying the number of seeds in the plan. The following scenario 
illustrates how striving for maximum efficiency would help decrease the likely-hood of 
high dose regions outside of the prostate and therefore the number of extra-prostatic 
seeds. During the planning process, seeds should be first placed inside the prostate. High 
dose regions inside the prostate are already constrained by the PTV V I50, and V200. 
Therefore, as the PTV V I00 increases and it becomes more difficult to place seeds within 
the prostate (i.e. to limit high doses to the prostatic urethra and PTV), one is forced to 
place seeds outside the prostate until the PTV VI00 reaches close to or above 95 %. This, 
however, cannot be done by placing many seeds far outside of the prostate. While doing
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so may increase the PTV V100 and limit the high doses within the PTV, at some point, 
the PTV VI00 will increase only marginally and/or the number of seeds will increase 
such that PTV V I00 / #seeds begins decreasing. That is, efficiency is decreased. 
Overcrowding of seeds within or outside the prostate is also discouraged because the 
metric will also decrease if seeds are too close together, and dose is too concentrated in 
one area compared to the number of seeds used.
3.2 Manual Oblique Planning technique
This section is an expansion and overview of sections 2.2.3(Plan types and criteria), and 
2.4.1( Planning Study). It is a guideline of techniques used this work for generating 
oblique plans and may be useful for others attempting to reproduce this work or generate 
oblique plans of their own. There are obviously many ways of generating an oblique plan, 
and the following only describes the manual techniques used for this study.
As previously mentioned in the oblique plans were created by adapting parallel 
non template plans, which were created by adapting parallel template plans. Transverse 
slices of the three different plans for the 60 cc prostate of Subject #2 are shown in Figure 
3.1. Oblique plans may be created from scratch, but possible methods of doing so are not 
discussed here.
Starting with a template based plan (Figure 3.1 (a)), removing the template allows 
one to translate the needles more to the periphery of the prostate, and move needles closer 
to the pubic arch. This provides more coverage to the underdosed antero-lateral parts of 
the prostate, and increases the beneficial effects of peripheral loading. Notice in Figure 
3.1(b) that peripheral needles (shaded red) are placed in a concentric ring like fashion, 
near the entire periphery of the prostate. If the peripheral needles are connected by an 
imaginary line, once can see that adjacent peripheral needles are spaced somewhat evenly 
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Figure 3.1: Plan adaptation for Subject #2’s 60 cc prostate, (a) a Parallel Template 
Plan is adapted into (b) a Parallel No Template plan, which is adapted into (c) an 
Oblique Plan.
An inner concentric ring (shaded blue) is created near the urethra with the four 
needles originally at 5F, 5H, and 3F, 3H. Most of the coverage around the urethra can be 
achieved using these four needles placed near the prostatic urethra, with two on either 
side of the midline of the prostate,
Placing the needles that are closest to the rectum and to the midline of the prostate 
(template positions IF and 1H in Figure 3.1(a)) to more optimal locations is also possible 
to avoid overdosing the rectum. Two such needles, one on either side of the midline of 
the prostate could suffice to give dose to the mid posterior region of the prostate. Usually, 
each of these needles only contains a couple of seeds at the base and apex.
With the peripheral needles pushed more peripherally, low dose regions are 
created at the base and apex of the prostate and sometimes also in the central parts of the 
prostate. This is alleviated by ensuring that some needles (shaded mustard yellow Figure 
3.1(b)) are moved into or kept in the central lateral parts of the prostate. Four such 
needles existed for the parallel no template plan in Figure 3.1(b), (only three are visible 
because one needle exists inferiorly to the slice shown). Another way to achieve coverage 
in the base and apex is to modify the depth and extend the seed loading pattern of the 
needles shaded in blue or mustard yellow in the superior-inferior direction.Adapting the 
parallel no template plan into the oblique plan (Figure 3.1(c)) primarily involves angling 
the needles closest to the pubic arch upwards into the antero-lateral parts of the prostate.
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This creates low dose regions due to needle divergence, particularly at the base. This can 
be remedied by inserting additional needles that reach the base and apex (shaded green in 
Figure 3.1(c)) between the peripheral ring of needles (shaded red) and inner ring (blue). 
Further adjustments can be made to the depths, positions, and seed loading patterns of the 
non-peripheral needles (shaded blue, green or mustard yellow) to optimize the dose 
coverage at the base and apex.
Translating and angling needles in this manner can lead to an even distribution of 
needles that avoids high doses near the urethra and rectum while achieving coverage in 
the parts of the prostate blocked by the pubic arch.
3.3 Phantom delivery workflow limitations and future work
The main limitation with the current delivery workflow is that it is time consuming. The 
phantom study work presented above was the third attempt of delivering the same plan to 
a phantom. All three phantom experiments took approximately 4 hours from probe 
insertion to withdrawal of the last needle for a single operator performing all delivery 
tasks. Small workflow adjustments, however, can help decrease this problem drastically, 
as will be explained here.
The main issue is the inherent difficulty of accurately guiding oblique needle 
trajectories and depths, which are both independent actions. The first two phantom 
experiments suffered from inserting a few needles to wrong depths, and thus having a 
slightly larger standard deviation in SUPINF displacement errors, although they had good 
ANTPOST and LEFTRIGHT (e.g. trajectory) accuracy.
The needle trajectory is mostly dependent on accurate positioning of the 
mechatronic guidance arms, which can be done quickly and accurately. Needle insertion 
depth, however, is difficult to guide with the 3D cube images, as was done in all phantom 
deliveries. This was partly due to probe scanning and image processing time that causes 
an image update lag of ~1 sec for certain large needle angles. The phantom also creates 
an interesting challenge that makes it difficult to adjust the depth of an improperly 
inserted needle because the phantom becomes structurally damaged by the needle
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insertion, causing scatter. On occasion, it was difficult to observe the needle in the 3D 
cube views during insertion, leading to re-insertions. This occurred, for example, if the 
needles were inserted too quickly, or were not rotated sufficiently to counteract needle 
deflections caused by the beveled tip. The scatter makes visualizing the needle tip 
difficult. Compensation for needle deflection to ensure accurate needle trajectories is also 
slow due to image lag, but could be done accurately by rotating the needle during 
insertion 1. The needles in this phantom study were rotated but at inconsistent rates due to 
manual insertions.
Compared to oblique needles, parallel trajectories are much easier to deliver since 
the acoustics waves are not deflected away, and only a single probe angle needs to be 
used for visualization without the need for 3D image scanning. The image lag and 
phantom damage were the most difficult hurdles to inserting needles quickly and 
achieving good depth accuracy. By inserting the needles slowly and rotating them, 
however, accurate needle trajectory and depth can be achieved. Delivering needles as 
slowly as was done in this phantom study though, is not clinically acceptable.
The speed and accuracy issues, however, can potentially all be overcome by 
improvements to the needle guidance work flow. What needs to be done is to overlay the 
intended needle trajectory on the live transducer video feed. The high temporal resolution 
of US imaging allows one to clearly visualize moving objects such as needles, tips of 
needles, or seeds. Even with scatter or low image contrast, moving the needle or seed in 
some way clearly distinguishes it from stationary structures.
Another limitation of the phantom study is that the needles were not inserted by 
an oncologist or urologist, but by an investigator who knows the mechanical system well 
but lacks clinical experience in needle insertions. In order to assess the feasibility of 















Figure 3.2: Hypothetical visual guidance windows, (a) Needle and needle tip are 
easily resolved in the live side-firing linear transducer array. A vertical orange line 
can indicate and be moved left and right to change the transverse cube slice (b). 
Transverse view of the 3D cube. A red line can indicate and be manipulated to 
change the probe angle, (c). A coronal view can show the LEFTRIGHT trajectory of 
the needle.
The live side-firing US linear transducer array video feed is very useful for 
visualizing the intended position of needles in the plane of the side crystal. A screen 
capture of a side-firing linear array image is shown in Figure 3.2(a). With respect to the 
coordinate system of the side crystal image, the horizontal represents the SUPINF
75
direction, and the vertical represent some linear combination of the ANTPOST and 
LEFTR1GHT directions, depending on the probe angle. The SUPINF position of the 
actual needle tip can thus be quickly and accurately determined if the intended SUPINF 
position is overlaid on the side-firing linear array video feed, which is not currently done. 
The vertical position and angle of the needle with respect to the side-firing linear array 
coordinate system can also be guided by overlaying a projection of the needle’s path onto 
the side-firing linear transducer plane. The difficulty then is to guide the needle correctly 
in the out-of-plane direction. This can be done with the aid of the transverse and coronal 
slices of the 3D cube, shown in Figure 3.2(b-c). Two possible workflow solutions are 
described below to guide the needle in the out-of-plane direction. Both solutions involve 
only using the side-firing linear transducer (aka sagittal transducer) for imaging. The 
motivation for only using the sagittal crystal is that moving the probe in and out of the 
SUPINF direction using the transverse crystal can allow the prostate to slide off the end 
of the probe and lead to positional uncertainties.
3.3.1 Potential Solution one -  Limiting all needles to a plane coincident 
with the side-firing linear transducer array.
This solution involves modifying the planning technique, to plan all needles, whether 
they are parallel or oblique, to be coincident to a side-firing linear transducer array plane. 
This adds a constraint that decreases to the needles’ degree of freedom by one. In general, 
a needle has five degrees of freedom; two for positioning its tip, two for positioning is 
back, and one for its insertion depth. For this solution, however, there are four degrees of 
freedom; one each for the probe angle, the needle insertion depth, the needle’s distance 
from the probe, and the needle’s angle within the plane of the crystal image.
Planning in this manner would require adjustments to the planning system 
interface for manual planning or an automatic planning algorithm. Decreasing the degree 
of freedom by one decreases the search space of a potential planning optimization 
algorithm, and may make the problem easier to solve then having five degrees of freedom 
for needle position and angle.
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The real benefit of this method, however, is that conventional needle imaging 
techniques can be used and 3D guidance is not mandatory (e.g scanning about an angle). 
The transverse convex transducer array can be used to check the needle trajectory as is 
currently practiced by some oncologists. The intended needle position can be overlaid on 
the sagittal live feed and only one probe angle is required for each needle. This work flow 
is similar to what is currently used and would allow easier adoption of mechatronic 
guided oblique needle insertions in the clinic.
3.3.2 Potential Solution two -  Stepwise 3D needle guidance.
If a single probe angle cannot fully image the entire oblique needle, 3D needle scanning 
is required. Unfortunately, it is very difficult to visualize the needle when the probe is 
constantly moving.
This solution divides the needle insertion into steps. Each step involves three 
parts: 1) inserting the needle to a depth “checkpoint” and imaging the needle using a side­
firing linear array at a stationary probe angle, 2) once the tip reaches the “checkpoint”, a 
small angle 3D scan can be done to update the 3D cube and verify the needle’s out-of- 
plane trajectory, 3) adjustments to the needle’s bevel can be made based on the observed 
trajectory. This process is repeated for the next “checkpoint” or the intended position. A 
schematic of this procedure is shown in Figure 3.3.
Fortunately, the probe does not have to be precisely angled in order to visualize 
the needle tip due to the out-of-plane thickness of the side-firing linear transducer array 
acoustic waves. This means the number of checkpoints required can be minimized in 
order to minimize the delivery time. From experience delivering oblique needles, just two 
checkpoints may suffice for most out-of-plane needles. The exact process would need to 
be refined through testing.
This process is similar to the current techniques used by oncologists, in which 
they initially insert the needle and visualize its trajectory and depth using the transverse 
crystal, which also has high temporal resolution. Then they switch to the side-firing linear 
transducer array to finalize the needle’s depth. This two-part process can be problematic
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if the needle’s trajectory is seen to be incorrect in the transverse view. This can lead to 
multiple re-insertions, which increases tissue trauma. The method presented above can 
allow tracking the needle’s out-of-plane trajectory more often, and has the added benefit 
of viewing both transverse and coronal views using 3D imaging. This may decrease the 
chance of needle re-insertions. In fact, the goal will be to guide needles in a single 
insertion.
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Figure 3.3: Proposed Stepwise 3D Needle guidance schematic. Needle insertions can 
be guided by the live side crystal view in red outlines. This can be followed by 3D 
trajectory verification, which can be done using the coronal view (in green outline), 
and transverse view (not shown). The orange vertical lines in the side crystal images 
represent checkpoints and the position of the transverse slice to be shown.
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3.4 Other Future work
Further work needs to be done to deliver oblique plans both accurately and quickly. It has 
been shown to be accurate but the delivery is time consuming. The potential guidance 
solutions mentioned above will be tested. This will likely greatly improve delivery time, 
and may potentially increase SUPINF accuracy. Also, any potential relationships between 
seed displacement and needle angle will be explored to determine if seed placement error 
increases with increasing angle. This could not be done conclusively from the previous 
phantom study due a limited total number of seeds (e.g. number of seeds = 120).
Mock delivery studies must be performed by oncologists and brachytherapy teams 
in order to properly test the robustness of this new technology, and prepare the system for 
clinical use.
Widespread adoption of oblique needle low dose rate brachytherapy would be 
greatly improved if an inverse dose planning system that allows oblique needle 
placements is developed. As previously mentioned, no suitable algorithm currently exists. 
Without it, intraoperative planning and delivery, for example, would be very difficult.
The lessons learned from this work have more applications than to just low dose 
rate prostate brachytherapy. They system can be applied to other transperineal needle 
insertion procedures such as high dose rate brachytherapy, focal therapy, cryotherapy, or 
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